Immunogenicity and reactogenicity of the combined hepatitis A and B vaccine in young adults

Vaccine

Volumn 19, Issue 4-5, 2000, Pages 437-441

  Tsai, I Jung ^a   Chang, Mei Hwei ^a   Chen, Huey Ling ^a   Ni, Yen Hsuan ^a   Lee, Ping Ing ^a   Chiu, Tai Yuen ^a   Safary, Assad ^b  

^a NATIONAL TAIWAN UNIVERSITY   (Taiwan)

^b GLAXOSMITHKLINE BIOLOGICALS   (Belgium)

Author keywords

Combined hepatitis A and B; Hepatitis A; Hepatitis B; Immunogenicity; Reactogenicity

Indexed keywords

HEPATITIS A ANTIBODY; HEPATITIS A VACCINE; HEPATITIS B ANTIBODY; HEPATITIS B VACCINE;

ADOLESCENT; ADULT; ANTIBODY RESPONSE; ARTICLE; CLINICAL TRIAL; CONTROLLED CLINICAL TRIAL; CONTROLLED STUDY; DRUG MIXTURE; DRUG SAFETY; DRUG TOLERABILITY; FATIGUE; FEMALE; FEVER; HEADACHE; HEPATITIS A; HEPATITIS B; HUMAN; HUMAN EXPERIMENT; IMMUNOGENICITY; MALAISE; MALE; NAUSEA; NORMAL HUMAN; PRIORITY JOURNAL; RANDOMIZED CONTROLLED TRIAL; VACCINATION; VOMITING;

ADULT; FEMALE; HEPATITIS A; HEPATITIS A ANTIBODIES; HEPATITIS A VACCINES; HEPATITIS ANTIBODIES; HEPATITIS B; HEPATITIS B ANTIBODIES; HEPATITIS B VACCINES; HUMANS; MALE; SAFETY; VACCINES, COMBINED; VACCINES, SYNTHETIC;

EID: 0034668212     PISSN: 0264410X     EISSN: None     Source Type: Journal    
DOI: 10.1016/S0264-410X(00)00205-X     Document Type: Article

References (27)

1. Frosner G.G., Papaevangelous G., Butler R., et al. Antibody against hepatitis A in seven European countries. Am. J. Epidemiol. 110:1979;63-68.
2. Frosner G.G. Epidemiology of hepatitis A. Deirhardt F. Viral hepatitis: laboratory and clinical science. 1983;201-212 Marcel Dekker, New York.
3. Hadler S.C. Global impact of hepatitis A virus infection: changing patterns. Holliger F.B., Lemon SM, Margolis H.S. Viral hepatitis and liver diseases. 1991;41-120 Williams & Wilkins, Baltimore.
4. Gast I.D. Epidemiological patterns of hepatitis A in different parts of the world. Vaccine. 10:(suppl 1):1992;S56-S58.
5. Tsen K.T., Chang M.H., Tsen Y.J., et al. Hepatitis A virus infection in Taipei City in 1989. J. Formosan Med. Assoc. 90:(2):1991;138-140.
6. Brien H. Declining prevalence of antibodies to hepatitis A infection in Ireland. Scand. J. Infection Dis. 23:1991;135-140.
7. Papaevangelous G. Epidemiology of hepatitis A in Mediterranean countries. Vaccine. 10:(suppl 1):1992;S63-S66.
8. Hadler S.C., Webster H.M., Erben J.J., et al. Hepatitis A in daycare centers: a community-wide assessment. N. Engl. J. Med. 302:1980;1222-1227.
9. Clemens R., Safary A., Hepbern A., et al. Clinical experience with an inactivated hepatitis A vaccine. J. Infect. Dis. 171:(suppl):1995;S44-S49.
10. Werzberger A., Mensch B., Kuter B., et al. A controlled trial of a formalin-inacitvated hepatitis A vaccine in children. N. Engl. J. Med. 327:1992;453-457.
11. Innis B.L., Snitbhan R., Kunasol P., et al. Protection against hepatitis A by an inactivated vaccine. J. Am. Med. Assoc. 271:1997;1328-1334.
12. Beasley R.P., Hwang L.Y., Lin C.C., et al. Hepatocellular carcinoma and hepatitis B virus: a prospective study of 22,707 men in Taiwan. Lancet. 2:1981;1129-1133.
13. Buendia M.A. Hepatitis B viruses and carcinogenesis. Biomedicine and Pharmacotherapy. 52:(1):1998;34-43.
14. Chang M.H., Chen D.S., Hsu H.C., et al. Maternal transmission of hepatitis B virus in childhood hepatocellular carcinoma. Cancer. 64:1989;2377-2380.
15. Steven C.E., Beuslet R.D., Tsai J., et al. Vertical transmission of hepatitis B antigen in Taiwan. N. Engl. J. Med. 292:1975;771-774.
16. Wang V.C.W., Ip H.M.H., Reesink H.W., et al. Prevention of the HBsAg carrier state in newborn infants and HbeAg by admission of hepatitis B vaccine and hepatitis B immunoglobulin. Lancet. 1:1984;921-926.
17. Lo K.J., Tsai Y.T., Lee S.D., et al. Immunoprophylaxis of infection with hepatitis B virus in infants born to hepatitis B surface antigen-positive carrier mothers. J. Infect. Dis. 152:1985;819-822.
18. Chen D.S., Hsu N.H.M., Sung J.L., et al. A mass vaccination program in Taiwan against hepatitis B virus infection in infants of hepatitis B surface antigen-carrier mothers. JAMA. 257:1987;2597-2603.
19. Chen H.L., Chang M.H., Ni Y.H., et al. Seroepidemiology of hepatitis B virus infection in children: ten years of mass vaccination in Taiwan. JAMA 1996, Dec. 11. 276:(22):1996;1802-1803.
20. Chang M.H., Chen C.J., Lai M.S., et al. Universal hepatitis B vaccination in Taiwan and the incidence of hepatocellular carcinoma in children. N. Engl. J. Med. 336:1997;1855-1859.
21. Andre F.E., Safary A. Summary of clinical findings on Engerix-B, a genetically engineered yeast-derived hepatitis B vaccine. Postgrad. Med. J. 63:(suppl. 2):1987;169-178.
22. Szmuness W., Steven C.E., Harley E.J., et al. Hepatitis B vaccine: demonstration of efficacy in a controlled clinical trial in a high risk population in the United States. N. Engl. J. Med. 303:1980;833-841.
23. Poovorawan Y., Sanpavat S., Pongpunlert W., et al. Protective efficacy of a recombinant DNA hepatitis B vaccine in neonates of HBe antigen-positive mothers. J. Am. Med. Assoc. 261:1989;3278-3281.
24. Leroux-Roels G., Morean E., Desombere I., et al. Safety and immunogenicity of a combined hepatitis A and hepatitis B vaccine in young healthy adults. Scand. J. Gastroenterol. S1:1996;1027-1031.
25. Kallinowski B., Bock H.L., Clemens R., et al. Immunogenicity and reactogenicity of a combined hepatitis A/B vaccine: first results. Liver. 16:1996;271-273.
26. Theolen S., van Damme P., Leentvaar-Kuypers A., et al. The first combined vaccine against hepatitis A and B: an overview. Vaccine. 17:1999;1657-1662.
27. Ambrosch F., Andre F.E., Delom, et al. Simultaneous vaccination against hepatitis A and B: results of a controlled study. Vaccine. 10:(suppl. 1):1992;S142-S145.